Academic Editor: Peter Mariuz
Throughout the United States, MRSA infections have increased dramatically in healthy adults and children without more commonly healthcare-associated MRSA (HA-MRSA) risk factors, such as recent hospitalization or surgery, indwelling catheter or residence in a long-term care facility [
HIV infection appears to be an independent risk factor for MRSA infections in adults, and MRSA infections occur at higher rates in HIV-infected adults [
Little is known about the epidemiology of MRSA infections in HIV-infected children and adolescents [
The Longitudinal Epidemiologic Study to Gain Insight into HIV/AIDS in Children and Youth (LEGACY) study is a CDC-funded, observational, prospective cohort study of HIV-infected children, and adolescents enrolled between birth and 24 years of age from 22 HIV specialty centers across the US. This study population was selected using a 3-stage cluster probability proportional to size sampling method to encourage a broad selection of HIV-infected infants, children and adolescents receiving care in geographically diverse small, intermediate, and large-sized facilities. This study was approved by the Institutional Review Board (IRB) of the CDC and the IRBs of all local study sites. A consolidated 301(d) Certificate of Confidentiality was obtained for LEGACY to provide an added level of strict privacy protection for participants. Between November 2005 and June 2007, at least 80% of eligible HIV-infected youth presenting for care at LEGACY clinic sites were offered enrollment. Participation was voluntary. Written informed assent and consent were obtained from minors and parents, as appropriate. The medical records of participants were reviewed, and data recorded on all visits during the study period were abstracted by trained data abstractors. Data collected included demographics (i.e., age, race, ethnicity, gender, educational level); mode of HIV infection (i.e., perinatal, breastfeeding, heterosexual activity, homosexual activity, sexual abuse, blood transfusion and injection drug use (IDU)); clinical diagnoses; antiretroviral (ARV) and non-ARV medications; immunizations; laboratory test results, including CD4 cell counts, plasma HIV RNA viral loads, results of HIV genotypic and phenotypic ARV resistance tests, chemistries, hepatitis testing, and urinalyses; reproductive history (i.e., age of menarche, sexual activity, contraceptive use, history of previous pregnancies and diagnosed sexually transmitted infections); psychosocial data (i.e., HIV disclosure status, substance abuse, sexual history, caregiver data); mortality data. Highly active antiretroviral therapy (HAART) was defined as treatment with at least three ARV drugs at the same time.
This analysis included data on participants with clinical and laboratory data available from at least one visit in 2006. A case of MRSA infection was defined as an individual who had any mention of MRSA as either a reason for hospitalization, as a diagnosis listed in a medical visit, or as the organism isolated from a culture at any visit in 2006. Participants with no mention of MRSA at any 2006 visit were considered as not having MRSA (MRSA noncases). Person-time of observation was calculated using January 1, 2006 as the study start date for individuals with a visit before 1/1/06 or the first visit in 2006 if they did not have a visit before 1/1/06. Time to event for MRSA cases was censored at the date of their MRSA infection. Time to event for non-MRSA cases was censored either at 12/31/06 for those with a visit after 12/31/06 or at their last visit in 2006 if they were not followed into 2007. For MRSA cases, age was calculated as the age at MRSA diagnosis. CD4 cell count and percentage, HIV RNA viral load (viral load), HAART use, and absolute neutrophil count (ANC) were defined as the closest value before MRSA diagnosis. For the MRSA noncases, age, CD4 cell count, viral load, HAART use (yes/no), and ANC were determined at the first visit in 2006. Mode of HIV transmission was defined as (i) vertical (mother-to-child) or perinatal, (ii) behavioral, or (iii) other or unknown. Behavioral mode of HIV transmission included injection drug use and sexual exposure. Demographic, psychosocial, and HIV clinical factors were examined as predictors of risk for MRSA infection using the chi-square test and Fisher's exact test for categorical variables and the
Clinical and laboratory data were available from 1,813 subjects with clinical and laboratory data available from at least one visit in 2006 from 16 sites. Fourteen MRSA infections (all culture confirmed) occurred among 1,813 subjects and 1,267 person-years of followup for an incidence of 772 cases per 100,000 persons and an incidence rate of 11.1 infections per 1,000 patient-years (PY) of observation (95% confidence interval (CI): 11.06–11.14). Median follow-up time was 0.79 years for the MRSA-infected case-patients and 0.80 years for the MRSA-uninfected patients. Seven (0.45%) subjects who were perinatally infected with HIV had MRSA infections for an incidence of 6.8 infections per 1,000 PY (95% CI, 1.8–11.8). Six (1.9%) behaviorally HIV-infected subjects had an MRSA infection incidence of 33.3 infections per 1,000 PY (95% CI, 5.6–61). One MRSA-infected case-patient acquired HIV infection in childhood but HIV risk factors were not known; this child was classified as nonbehaviorally HIV infected. In most cases (11/14), MRSA was diagnosed and/or cultured at a visit in 2006 after at least one prior visit without MRSA infection. In the remaining three cases, MRSA was diagnosed and/or cultured at the first abstracted visit for LEGACY, in February, April, and July, respectively.
All MRSA-infected case-patients were non-Hispanic black; eight (57%) were female and six (43%) received HIV care in Maryland. None reported use of intravenous drugs. Median age was 18 years (range, 6–24). Median CD4 cell count and percentage were 383 cells/mm3 and 20%, respectively. Six (43%) subjects were treated with HAART, but only 1 (7%) had a suppressed viral load (<400 copies/mL). Overall, nine (64%) MRSA-infected case-patients had HIV-1 viral loads >10,000 copies/mL. One subject was receiving cotrimoxazole prophylaxis; none were taking systemic steroids.
Four (29%) case-patients were hospitalized at time of MRSA diagnosis, including one subject whose blood culture grew MRSA and whose urine culture grew
Compared with MRSA-uninfected participants, MRSA case-patients were older (17 versus 14 years,
In multivariate analysis (
This analysis provides the first estimate of annual incidence of MRSA infections in a well-defined cohort of children and adolescents with HIV infection since the emergence of the CA-MRSA epidemic. The predominance of SSTIs, the low rate of bacteremia or other invasive infections, and the very low rate of clindamycin resistance are more typical of CA-MRSA infections and suggest that most of these infections were caused by CA-MRSA rather than HA-MRSA strains [
Two of the independent risk factors for MRSA infection—black race and Maryland site—observed in this analysis may reflect the higher rates of MRSA infection in blacks and geographic variability in MRSA rates in communities across the United States [
While HIV-infected children in this study had a higher rate of MRSA, the spectrum and severity of infections were remarkably similar to the pattern observed in otherwise healthy children [
It is not known whether HIV-associated changes in innate immunity increase MRSA risk. Abnormal chemotaxis and phagocytosis have been documented in HIV infection [
This study is limited by its reliance on data abstracted from existing medical records and the lack of availability of bacterial isolates for strain typing to confirm similarity to CA-MRSA strains. The risk of recurrent infections was not evaluable because of incomplete data about MRSA infections before and after 2006. The CD4 count used for each case was the value obtained closest to the time of MRSA diagnosis. Most (9/14) CD4 counts were obtained within 3 months prior to MRSA and all but two within the prior 6 months, so the CD4 values used are expected to accurately reflect the CD4 count at the time onset of MRSA infection. Estimates of MRSA infection rates in this HIV-infected cohort are extrapolated from a small number of events and may be higher than published estimates for healthy children, because HIV-infected children may have more frequent medical care appointments, are often followed by infectious disease specialists, and may be more intensively evaluated for suspected infections. Because we did not have a control group of HIV-uninfected children and did not exclude children based on contact with healthcare in this study, we cannot conclude that HIV infection rather than other risk factors such as poverty, contact with the health care system, or other factors may have played a more significant role. Finally, differences in MRSA rates by geographic location may represent differences in routine practices for evaluation of soft tissue and other infections such as the culturing of purulent drainage from soft tissue abscesses as part of routine management.
MRSA infections in a cohort of HIV-infected children and adolescents occurred at a rate higher than that observed among healthy children in the general population, but invasive disease was uncommon. Susceptibility profiles of MRSA isolates indicated that most infections were caused by CA-MRSA strains. Our analysis suggests that there was an increased incidence of MRSA infection in HIV-infected children compared to the general population, as has been seen in HIV-infected adults. Geographic location, black race and increased VL, but not immunosuppression, were independently associated with MRSA risk. The high prevalence of MRSA in communities most affected by pediatric HIV infection as well as poorly controlled or advanced HIV infection might have contributed to higher rates of MRSA infection in HIV-infected youth.
The authors declare there is no conflict of interests.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the Centers for Disease Control and Prevention or the institutions with which the authors are affiliated.
The authors thank investigators and abstractors at the LEGACY study sites: Edward Handelsman, Hermann Mendez, Jeffrey Birnbaum, Betsy Eastwood, Diana Mason, Ava Dennie, Gail Joseph (SUNY Downstate, Brooklyn NY*), Ninad Desai, Liberato Lao (Kings County Hospital Center, Brooklyn NY*) Andrew Wiznia, Joanna Dobroszycki, Tina Alford (Jacobi Medical Center, Bronx NY**), Lisa-Gaye Robinson, Tina Alford (Harlem Hospital, New York City NY**), Arry Dieudonne, Peggy Latortue (University of Medicine and Dentistry of New Jersey, Newark NJ*), Tamara Rakusan, Sarah McLeod, Deborah Rone (Children's National Medical Center, Washington DC**), Richard Rutstein, Ariane Adams, Rebecca Thomas, Olivia Prebus (The Children's Hospital of Philadelphia, Philadelphia PA**), George K. Siberry, Allison Agwu, Rosanna Setse, Jenny Chang (The Johns Hopkins Medical Institutes, Baltimore MD**), Steven Nesheim, Sheryl Henderson, Vickie Grimes, Julianne Gaston (Emory University, Atlanta GA**), Clemente Diaz, Francisca Cartagena (University of Puerto Rico, San Juan PR**), Delia Rivera, Dianne Demeritte (University of Miami, Miami FL**), Jose Carro, William Blouin, Vivian Hernandez-Trujillo, Marcelo Laufer, Dianne Demeritte (Miami Children's Hospital, Miami FL**), Ana Puga, Yanio Martinez (Children's Diagnostic and Treatment Center, Fort Lauderdale FL*), Patricia Emmanuel, Janet Sullivan, AJ Sikes, (University of South Florida, Tampa FL*), Mobeen Rathore, Kristy Champion, Ellen Trainer (University of Florida, Jacksonville FL**), Mary E. Paul, Samuel B. Foster, Amy Leonard (Baylor College of Medicine/Texas Children's Hospital, Houston TX**), Gloria Heresi, Gabriela del Bianco (University of Texas-Houston, Houston TX**), Theresa Barton, Janeen Graper (University of Texas-Southwestern/Children's Medical Center, Dallas TX**), Toni Frederick, Andrea Kovacs, Suad Kapetanovic, Michael Neely, LaShonda Spencer, Mariam Davtyan, Uhma Ganesan (University of Southern California, Los Angeles CA**), Marvin Belzer, Molly Flaherty (Children's Hospital of Los Angeles, Los Angeles CA*), Jane Bork, Mariam Davtyan (Loma Linda University Medical Center, Loma Linda CA*), Dean Blumberg, Lisa Ashley, Molly Flaherty (University of California—Davis, Sacramento CA**). In addition, they thank Kathy Joyce, Julie Davidson, Sharon Swanigan, Patrick Tschumper, Amanda Fournier and Kathleen Paul at Westat Inc. (Rockville MD) for contractual support, site monitoring and data management support. They also thank Vicki Peters (New York City Department of Health and Mental Hygiene) who has served as a consultant to the LEGACY project. They are also grateful to the patients and caregivers who consented to participate in LEGACY, as well as the administrative personnel at each study site, Westat and CDC. They thank Jenine Milum who provided data management assistance for this analysis. The LEGACY project was funded by the Centers for Disease Control and Prevention, Atlanta GA, contract number 200-2004-09976. Contributed patient data to: *2006 cohort only and **All LEGACY cohorts.
Methicillin-resistant
Human immunodeficiency virus.
Characteristics of Participants with and without MRSA Infections in the LEGACY Study, 2006.
| Characteristic | MRSA cases | Non-MRSA cases | Odds ratio | 95% CI |
|
|---|---|---|---|---|---|
| Female, | 8 (57%) | 989 (55%) | 1.1 | 0.4, 3.2 | 0.87 |
| Non-Hispanic black, | 14 (100% ) | 1237 (69%) | 1.5 | 1.4, 1.5 | 0.012 |
| Behavioral risk factor for HIV acquisition, | 6 (43%) | 310 (17%) | 3.6 | 1.2, 10.4 | 0.012 |
| Viral load >1000 copies/mL, | 12 (86%) | 910 (51%) | 5.8 | 1.3, 25.8 | 0.01 |
| Not receiving HAART, | 8 (57%) | 980 (54%) | 1.1 | 0.4, 3.2 | 0.85 |
| ANC1 <1500, cells/ | 3 (30%) | 464 (27%) | 1.1 | 0.3, 4.5 | 0.84 |
| Care site, | 10.12 | 3.5, 29.7 | <0.0001 | ||
| Maryland | 6 (43%) | 124 (7%) | |||
| Georgia | 2 (14%) | 143 (8%) | |||
| Florida | 3 (21%) | 488 (27%) | |||
| Washington D.C. | 1 (7%) | 141 (8%) | |||
| Pennsylvania | 1 (7%) | 99 (6%) | |||
| Texas | 1 (7%) | 206 (11%) | |||
| New York | 0 (0%) | 294 (16%) | |||
| Puerto Rico | 0 (0%) | 87 (5%) | |||
| California | 0 (0%) | 176 (10%) | |||
| New Jersey | 0 (0%) | 41 (2%) | |||
| History of eczema, | 2 (14%) | 236 (13%) | 1.1 | 0.2, 5.0 | 0.9 |
| Age ≥15 yrs, | 10 (71%) | 785 (44%) | 3.2 | 1.0, 10.3 | 0.037 |
| Mean/median age, years | 17.1/18.0 | 13.8/14.0 | — | — | <0.05 |
| CD4 count <200, cells/ | 4 (29%) | 185 (11%) | 3.4 | 1.1, 10.9 | 0.03 |
| CD4 percent <20%, | 7 (50%) | 414 (24%) | 3.2 | 1.1, 9.3 | 0.02 |
| Mean/median CD4 count, cells/ | 390.9/383.0 | 680.3/574.0 | — | — | 0.029 |
| Mean/median CD4 % | 17.6/19.5 | 26.9/27.0 | — | — | 0.0016 |
| History of AIDS-defining illness | 2 (18%) | 364 (25%) | 0.67 | 0.1, 3.1 | 0.61 |
1ANC: absolute neutrophil count.
2Comparing Maryland versus all others.
MRSA: methicillin-resistant
Factors associated with MRSA infection in multivariable analysis, the LEGACY Study, 2006.
| Initial multivariable model ( | Final reduced multivariable model ( | |||||
|---|---|---|---|---|---|---|
| Characteristic | aOR | 95% CI |
| aOR | 95% CI |
|
| Maryland care site1 | 7.4 | 2.4, 23.2 | 0.0006 | 9.0 | 3.0, 26.8 | <0.0001 |
| CD4 <200 cells/ | 1.6 | 0.43, 5.7 | 0.50 | — | — | — |
| Behavioral risk3 | 1.9 | 0.5, 7.3 | 0.34 | — | — | — |
| Viral load >1000 copies/mL4 | 4.6 | 1.0, 22.0 | 0.056 | 5.9 | 1.3, 26.5 | 0.02 |
| Age ≥15 years5 | 1.4 | 0.30, 6.1 | 0.69 | — | — | — |
| Non-Hispanic black6 | Und7 | Und7 | 0.035 | Und7 | Und7 | 0.044 |
Comparing: 1Maryland care site versus all other care sites; 2CD4 <200 cells/
aOR: adjusted Odds Ratio.
MRSA: methicillin-resistance